DDInter786 DDInter1016
Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aminoglutethimide
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Fostemsavir may lead to a major life threatening interaction when taken with Ribociclib
Fostemsavir may lead to a major life threatening interaction when taken with Macimorelin